Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1979-8-29
pubmed:abstractText
To explore the role of the human intestine as a source of apolipoproteins, we have studied intestinal lipoproteins and apoprotein secretion in two subjects with chyluria (mesenteric lymphatic-urinary fistulae). After oral corn oil, apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II) output in urine increased in parallel to urinary triglyceride. One subject, on two occasions, after 40 g of corn oil, excreted 8.4 and 8.6 g of triglyceride together with 196 and 199 mg apoA-I and on one occasion, 56 mg apoA-II. The other subject, after 40 g corn oil, excreted 0.3 g triglyceride and 17.5 mg apoA-I, and, after 100 g of corn oil, excreted 44.8 mg apoA-I and 5.8 mg apoA-II. 14.5+/-2.1% of apoA-I and 17.7+/-4.3% of apoA-II in chylous urine was in the d < 1.006 fraction (chylomicrons and very low density lipoprotein). Calculations based on the amount of apoA-I and apoA-II excreted on triglyceride-rich lipoproteins revealed that for these lipid loads, intestinal secretion could account for 50 and 33% of the calculated daily synthetic rate of apoA-I and apoA-II, respectively. Similarly, subject 2 excreted 48-70% and 14% of the calculated daily synthetic rate of apoA-I and apoA-II, respectively. Chylous urine contained chylomicrons, very low density lipoproteins and high density lipoproteins, all of which contained apoA-I. Chylomicrons and very low density lipoproteins contained a previously unreported human apoprotein of 46,000 mol wt. We have called this apoprotein apoA-IV because of the similarity of its molecular weight and amino acid composition to rat apoA-IV. In sodium dodecyl sulfate gels, chylomicron apoproteins consisted of apoB 3.4+/-0.7%, apoA-IV 10.0+/-3.3%, apoE 4.4+/-0.3%, apoA-I 15.0+/-1.8%, and apoC and apoA-II 43.3+/-11.3%. Very low density lipoprotein contained more apoB and apoA-IV and less apoC than chylomicrons. Ouchterlony immunodiffusion of chylomicron apoproteins revealed the presence of apoC-I, apoC-II, and apoC-III. In contrast, plasma chylomicrons isolated during a nonchyluric phase revealed a markedly altered chylomicron apoprotein pattern when compared with urinary chylomicrons. The major apoproteins in plasma chylomicrons were apoB, apoE, and the C peptides: no apoA-I or apoA-IV were present in sodium dodecyl sulfate gels indicating that major changes in chylomicron apoproteins occur during chylomicron metabolism. When incubated in vitro with plasma, urinary chylomicrons lost apoA-I and apoA-IV and gained apoE and apoC. Loss of apoA-I and apoA-IV was dependent upon the concentration of high density lipoproteins in the incubation mixture. These studies demonstrate that the human intestine secretes significant amounts of apoA-I and apoA-II during lipid absorption. Subsequent transfer of apoproteins from triglyceride-rich lipoproteins to other plasma lipoproteins may represent a mechanism whereby the intestine contributes to plasma apoprotein levels.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-13428781, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-13533462, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-13942784, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-14907713, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-176290, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-178981, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-182724, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-194921, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-196292, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-197124, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-197185, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-202615, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-207739, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-208597, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-210174, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-213720, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-217374, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-350901, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-361487, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-365664, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-414755, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-4335135, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-4349053, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-4369025, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-4371855, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-5059205, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-5355348, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-5688076, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-5824073, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-5959431, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-632283, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-690511, http://linkedlifedata.com/resource/pubmed/commentcorrection/221544-932206
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0021-9738
pubmed:author
pubmed:issnType
Print
pubmed:volume
64
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
233-42
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1979
pubmed:articleTitle
Human intestinal lipoproteins. Studies in chyluric subjects.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.